MBII: Marrone Bio Innovations adds to credit facility based on short term assets. Our estimates do not include any financials from the recent acquisitions.
Byline: Zacks Small Cap Research
By Ian Gilson, PhD, CFA
READ THE FULL MBII RESEARCH REPORT
Marrone Bio Innovations (NASDAQ: MBII) has increased its line of credit based on accounts receivable from $7 million to $20 million and has added a line of credit backed by its inventory. Both additional funds will be made available from LSQ Funding Group [ https://lsq.com].
Small high growth companies frequently our pace their cash as they try to balance cash/accounts receivable/inventories/accounts payable with operating expenses. This is especially difficult when revenue is highly seasonal and costs occur in different accounting periods than accounts receivable are paid.
Lending organizations have a lot more access to the financials than do analysts so it is encouraging that LSQ Funding has such confidence in Marrone Bio Innovations to guarantee access to $18 million of additional funding.
Our estimates do not include any data from the recent acquisitions since no current or historical data is available at this time. When the impact of the acquisitions becomes available we will adjust our forecasts accordingly.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. Full Disclaimer HERE.
|Printer friendly Cite/link Email Feedback|
|Author:||Zacks Small Cap Research|
|Date:||Jan 10, 2020|
|Previous Article:||Lime Shutting Down In 12 Markets Over Profitability Concerns.|
|Next Article:||Mid-Morning Market Update: Markets Open Higher; Eli Lilly To Buy Dermira For $18.75/Share.|